Jagsonpal Pharmaceuticals Ltd appointed Anil Kumar Matai as a Non-Executive Independent Director effective June 25, 2026, to strengthen its governance structure with leadership experience in the pharmaceutical and healthcare sectors. The appointment is for a term of five years and is subject to the approval of the company's shareholders. The Board of Directors approved the appointment based on the recommendation of the Nomination and Remuneration Committee during a meeting held on June 25, 2026.

The company affirmed that Matai is not debarred or disqualified from being appointed as a director by SEBI, the Ministry of Corporate Affairs, or any other statutory authority. The disclosure confirmed there are no inter-se relationships between Matai and the other members of the Board. The appointment was communicated to BSE Ltd and the National Stock Exchange of India Ltd pursuant to Regulation 30 of the SEBI LODR Regulations.

Anil Matai is a seasoned life sciences leader with over 35 years of experience across multinational corporations, Indian pharma companies, and private equity. He currently serves as the Director General of the Organisation of Pharmaceutical Producers of India (OPPI). His previous roles include CEO of Novartis India Ltd., President & MD of Zydus Healthcare Ltd., and Operating Partner at Jashvik Capital.

Appointment Details

Infinity Holdings has confirmed that it did not create any encumbrance on its shares in Jagsonpal Pharmaceuticals Limited during the financial year ended March 31, 2026. The declaration, submitted on April 06, 2026, was made in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any pledging or encumbrance of shares to ensure transparency for shareholders.

The disclosure covers both direct and indirect encumbrances. Infinity Holdings stated that no such activity was undertaken by it or by persons acting in concert with it throughout FY26. The filing was addressed to the Board of Directors and the Company Secretary of Jagsonpal Pharmaceuticals Limited , with copies sent to the Audit Committee and related entities such as Infinity Capital and Infinity Portfolio Holdings.

Regulatory Context

The filing is a mandatory compliance requirement under SEBI takeover regulations. It serves to inform the stock exchanges and the company's shareholders about the status of the promoter's holdings. A nil encumbrance status indicates that the promoter's shares are free from pledges, which is generally viewed as a positive indicator of corporate governance and financial stability.

Key Details of the Disclosure

The letter was signed by Ahmad Tariq Hossanee, Director of Infinity Holdings. The confirmation provides clarity to investors regarding the unencumbered status of the promoter's shareholding in the pharmaceutical company for the specified period.